Aratana Therapeutics says no benefit to post-licensing marketing studies

Aratana Therapeutics Inc. (NYSE: PETX) said that post-licensing marketing studies of canine lymphoma products AT-004 and AT-005 will not fully capture market opportunities. The stock price plummeted $6.82 to close at $10.67.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.